AHP-EMTA 500mg IV Inj 1`s

Oncologists give it as an intravenous infusion, alone or with cisplatin.

AHP-EMTA 500mg IV Injection Ingredients and Usage

AHP-EMTA 500mg IV Injection contains pemetrexed, a multitargeted antifolate antineoplastic agent. An antifolate is a drug that blocks the body's use of folate, a vitamin cancer cells need to make DNA. Oncologists use AHP-EMTA to treat specific advanced cancers.

AHP-EMTA 500mg IV Injection treats non-squamous non-small cell lung cancer as first line therapy with cisplatin. It also serves as maintenance and second line monotherapy for this cancer. Doctors combine AHP-EMTA with cisplatin to treat unresectable malignant pleural mesothelioma.

How Does AHP-EMTA 500mg IV Injection Work?

AHP-EMTA 500mg IV Injection blocks three folate dependent enzymes that cancer cells need to divide. Pemetrexed primarily inhibits thymidylate synthase, the enzyme that builds thymidine for new DNA. It also inhibits dihydrofolate reductase and glycinamide ribonucleotide formyltransferase.

The reduced folate carrier transports pemetrexed into the cell, where enzymes convert it into active polyglutamate forms. These forms block purine and pyrimidine synthesis, the building blocks of DNA and RNA. Cancer cells then stop dividing and die.

AHP-EMTA 500mg IV Injection Side Effects

AHP-EMTA 500mg IV Injection causes side effects typical of antifolate chemotherapy. Low blood counts, mouth sores, and fatigue are the most frequent effects.

• Myelosuppression (neutropenia, thrombocytopenia, anaemia)

• Mucositis and mouth sores

• Fatigue and weakness

• Nausea, vomiting, and diarrhoea

• Decreased appetite

• Skin rash

• Reduced kidney function

• Swelling of the feet and ankles (oedema)

Warnings

• Patients must take folic acid and vitamin B12 supplements before and during AHP-EMTA treatment. This supplementation reduces the risk of severe myelosuppression and mucositis.

• AHP-EMTA can cause severe bone marrow suppression, the main dose limiting toxicity. Doctors check blood counts before each cycle and adjust the dose accordingly.

• AHP-EMTA is not recommended for patients with creatinine clearance below 45 mL/min. The kidneys clear pemetrexed, so renal impairment raises toxicity risk.

• NSAIDs such as ibuprofen slow pemetrexed clearance and increase toxicity. Patients with reduced kidney function should avoid NSAIDs around each dose.

• AHP-EMTA causes embryo fetal harm and is contraindicated in pregnancy and breastfeeding. Both male and female patients must use effective contraception during treatment.

AHP-EMTA 500mg IV Injection Storage Conditions

Store AHP-EMTA 500mg IV Injection at room temperature below 30°C in its original carton to protect it from light. Do not freeze the vial, as freezing damages the product. Keep AHP-EMTA out of the reach of children, and let only trained hospital staff reconstitute and administer it.